AVT-001 is under clinical development by Avotres and currently in Phase II for Type 1 Diabetes (Juvenile Diabetes). According to GlobalData, Phase II drugs for Type 1 Diabetes (Juvenile Diabetes) have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AVT-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AVT-001 overview
AVT-001 is under development for the treatment of type I diabetes, lupus, relapsing remitting and progressive multiple sclerosis, transplantation, pemphigus, dermatomyositis psoriasis, psoriatic arthritis, rheumatoid arthritis, cutaneous lupus erythematosus, chronic graft rejection and vitiligo. It is administered through the intravenous route. The drug candidate consists of autologous dendritic cells and acts by targeting the Qa-1/HLA-E Restricted CD8+ regulatory T cells.
It was also under development for scleroderma and Crohn's disease.
Avotres overview
Avotres is a biotechnology company that develops and commercializes therapies for transplantation, autoimmune diseases and cancers. It is investigating AVT001 cell therapy to treat type 1 diabetes, Crohn’s disease, lupus, multiple sclerosis, pemphigus, psoriasis, rheumatoid and psoriatic arthritis, scleroderma and vitiligo; and AVT002, a monoclonal antibody (mAb) targeting melanoma and other tumors. The company is also developing AVT-Dx 001, a clinical diagnostic test for early detection of autoimmune diseases. Avotres is headquartered in Hanover, New Jersey, the US
For a complete picture of AVT-001’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
